Methenamine Hippurate Eql Pharma

Active Ingredient:: Methenamine Hippurate
Origin:: EU

Methenamine Hippurate Eql Pharma (Methenamine Hippurate)

Q: How does Methenamine Hippurate work?

In acidic urine (pH < 6.0), Methenamine Hippurate hydrolyses to release formaldehyde. Formaldehyde acts as a broad‑spectrum antibacterial agent, denaturing bacterial proteins and nucleic acids, thereby inhibiting the growth of uropathogens.

Q: What is the usual dose of Methenamine Hippurate?

The prescribed dose of Methenamine Hippurate is determined by the treating physician based on the patient’s condition, renal function, and urine pH. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Q: Is Methenamine Hippurate safe during pregnancy or breastfeeding?

Safety in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and after consultation with a healthcare professional.

Q: How do I order Methenamine Hippurate Eql Pharma from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Methenamine Hippurate compare with other urinary antiseptics?

Methenamine Hippurate differs from other urinary antiseptics such as nitrofurantoin or fosfomycin in that it requires acidic urine for activation. It provides a non‑systemic approach, releasing formaldehyde locally in the urinary tract, which can be advantageous for long‑term prophylaxis.

Q: How should Methenamine Hippurate be stored?

Store Methenamine Hippurate at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight or high humidity.

Q: How is Methenamine Hippurate administered?

Methenamine Hippurate is taken orally, usually with a full glass of water. It is important to maintain adequate hydration and, when possible, ensure urine remains acidic to optimise drug activation.

Q: What are the most serious risks associated with Methenamine Hippurate?

Serious risks include hematuria, severe allergic reactions such as anaphylaxis, metabolic acidosis, and rare cases of renal or hepatic impairment. Patients should seek immediate medical attention if they experience any of these symptoms.

Q: Who should not use Methenamine Hippurate?

Methenamine Hippurate should be avoided in patients with alkaline urine (pH ≥ 6.0) that cannot be acidified, those with severe renal or hepatic dysfunction, and individuals with known hypersensitivity to the drug or its components.

Methenamine Hippurate, the active ingredient in Methenamine Hippurate Eql Pharma, is a urinary antiseptic presented as an oral tablet for oral use. It is used to prevent recurrent urinary tract infections in adults.

GNH India supplies Methenamine Hippurate Eql Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eql Pharma Ab

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Methenamine Hippurate is a urinary antiseptic indicated for prophylaxis of urinary tract infections.

Recurrent urinary tract infections: reduces the frequency of infections in patients with a history of recurrence.
Catheter‑associated urinary infections: helps maintain sterile urine during short‑term catheterisation.
Post‑surgical urinary prophylaxis: used to prevent infection after urological procedures.

How It Works

Methenamine Hippurate is hydrolysed in acidic urine to release formaldehyde. The generated formaldehyde exerts a broad‑spectrum antibacterial effect by denaturing bacterial proteins and nucleic acids, thereby inhibiting the growth of uropathogens while sparing systemic tissues.

Side Effects

Methenamine Hippurate may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

Nausea: mild stomach upset.
Dyspepsia: discomfort or burning in the upper abdomen.
Metallic taste: transient alteration of taste perception.
Headache: mild to moderate intensity.
Skin rash: localized erythema or pruritus.

Serious or Rare Side Effects

Hematuria: blood in urine, indicating possible urinary irritation.
Severe allergic reaction: anaphylaxis, swelling of face or throat.
Metabolic acidosis: rare disturbance of acid‑base balance.
Renal impairment: worsening kidney function in susceptible individuals.
Hepatotoxicity: elevated liver enzymes in rare cases.

Precautions & Warnings

Before using Methenamine Hippurate, consider the following precautions.

Acidic urine requirement: ensure urine pH is below 6.0 for optimal drug activation.
Renal function: assess kidney function; dose adjustment may be needed in impairment.
Hepatic function: monitor liver enzymes in patients with liver disease.
Pregnancy and lactation: use only if clearly needed; discuss risks with a healthcare professional.
Concomitant urinary alkalinising agents: avoid or monitor as they may reduce efficacy.
Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Avoid Interactions

Methenamine Hippurate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

Urinary alkalinizers (e.g., sodium bicarbonate, potassium citrate): raise urine pH, reducing drug activation.
High‑dose vitamin C: may increase urinary pH and diminish effectiveness.

Moderate Interactions (Monitor Closely)

Loop diuretics: may alter urinary concentration, affecting drug hydrolysis.
Antacids containing magnesium or aluminum: can affect urinary pH indirectly.
Other urinary antiseptics: combined use may increase risk of adverse renal effects.

Frequently Asked Questions

Methenamine Hippurate is used as a urinary antiseptic to prevent recurrent urinary tract infections. It helps maintain sterile urine, especially in patients with a history of frequent infections or those undergoing short‑term catheterisation.

In acidic urine (pH < 6.0), Methenamine Hippurate hydrolyses to release formaldehyde. Formaldehyde acts as a broad‑spectrum antibacterial agent, denaturing bacterial proteins and nucleic acids, thereby inhibiting the growth of uropathogens.

The prescribed dose of Methenamine Hippurate is determined by the treating physician based on the patient’s condition, renal function, and urine pH. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and after consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methenamine Hippurate differs from other urinary antiseptics such as nitrofurantoin or fosfomycin in that it requires acidic urine for activation. It provides a non‑systemic approach, releasing formaldehyde locally in the urinary tract, which can be advantageous for long‑term prophylaxis.

Store Methenamine Hippurate at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight or high humidity.

Methenamine Hippurate is taken orally, usually with a full glass of water. It is important to maintain adequate hydration and, when possible, ensure urine remains acidic to optimise drug activation.

Serious risks include hematuria, severe allergic reactions such as anaphylaxis, metabolic acidosis, and rare cases of renal or hepatic impairment. Patients should seek immediate medical attention if they experience any of these symptoms.

Methenamine Hippurate should be avoided in patients with alkaline urine (pH ≥ 6.0) that cannot be acidified, those with severe renal or hepatic dysfunction, and individuals with known hypersensitivity to the drug or its components.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 06 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.